Latest News and Press Releases

- Initiated prospective study to collect coincident samples of oral fluid and blood following IRB approval - - Finalizing site selection at the University of Newcastle campus for the high-tech...

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government - -...

 – Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –  – Clinical Validation Study Results for SARS CoV2 Ab Test –  – Evaluating site locations for build out of...

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...

NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at...

H.C. Wainwright 23rd Global Investor Conference: September 13th - 15th Benzinga Healthcare Small Cap Conference: September 29th - 30th NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq:...

- Awarded $4.7 Million Government Grant Funding to support the building of a high-tech manufacturing facility - - Signs Strategic Partnerships with Johns Hopkins University, Wyss Institute from...

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...

NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners...